You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


ICR urges change as NICE rejects Keytruda plus chemotherapy

The Institute for Cancer Research (ICR) has called for change in the way immunotherapy drugs are researched and evaluated after the National Institute for Health and Care Excellence (NICE) handed MSD’s Keytruda plus chemotherapy a rejection.